SULFA.org Independent ยท Reference

Other sulfa drugs.

Beyond the antibiotics, diuretics, sulfonylureas, and carbonic anhydrase inhibitors, the sulfonamide family includes several drugs that resist easy classification: sulfasalazine, the sulfone dapsone, topical preparations like silver sulfadiazine and sulfacetamide eye drops, and a handful of other agents (sumatriptan, probenecid) that share the chemical group without the antibiotic-type reactivity.

Sulfasalazine
IBD and rheumatology โ€” metabolised to sulfapyridine with antibiotic-type arylamine.
Dapsone
A sulfone, not a sulfonamide; leprosy, dermatitis herpetiformis, PCP prophylaxis.
Topical sulfa
Silver sulfadiazine, sulfacetamide eye drops/lotions.
Edge cases
Sumatriptan, probenecid, zonisamide, tamsulosin (chemical relatives only).

Sulfasalazine

Sulfasalazine is unusual within the family. It is a prodrug, taken orally, split by colonic bacteria into two pieces: 5-aminosalicylic acid (5-ASA, the active anti-inflammatory agent in inflammatory bowel disease) and sulfapyridine. Sulfapyridine is structurally an antibiotic-type sulfonamide โ€” it carries the N4 arylamine. Most of the sulfa-related side effects of sulfasalazine come from the sulfapyridine moiety.

Sulfasalazine is used in inflammatory bowel disease (particularly ulcerative colitis), rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. People with documented sulfa antibiotic allergy may react to sulfasalazine, and clinicians often choose alternatives in this group. For inflammatory bowel disease, agents that deliver 5-ASA without the sulfa moiety (mesalamine, balsalazide, olsalazine) are widely used and avoid the issue.

Dapsone

Dapsone (4,4'-diaminodiphenyl sulfone) is a sulfone, not a sulfonamide. The chemistry is related but distinct: a sulfone has the โ€“SO2โ€“ group between two carbon-based groups, with no nitrogen in the central group. Dapsone is mentioned here because it is often grouped clinically with the sulfa drugs and shares some of their concerns.

Indications include leprosy (a cornerstone of multidrug therapy), dermatitis herpetiformis (the skin manifestation of celiac disease), Pneumocystis jirovecii pneumonia prophylaxis as an alternative to TMP-SMX, and several inflammatory dermatologic conditions. Major adverse effects include hemolytic anemia (especially in G6PD deficiency, where it can be severe โ€” G6PD testing is recommended before starting), methemoglobinemia, agranulocytosis (rare), and the dapsone hypersensitivity syndrome (a DRESS-like reaction with rash, fever, hepatitis, and eosinophilia).

Cross-reactivity between dapsone and sulfa antibiotics is debated. Some patients with sulfa antibiotic allergy tolerate dapsone; others do not. Caution is reasonable, particularly for patients with severe past reactions. The decision is the prescriber's.

G6PD testing before dapsone. Dapsone can cause severe hemolysis in G6PD-deficient patients. Pre-prescription G6PD testing is standard in many settings, particularly in populations with higher G6PD prevalence. More on G6PD.

Topical sulfa

Topical sulfa preparations are widely used. Silver sulfadiazine cream is applied to partial-thickness burns; the silver provides broad antimicrobial activity and the sulfadiazine adds further coverage. Its routine role in modern burn care has been questioned in some literature, but it remains common.

Sulfacetamide appears in ophthalmic drops and ointments (for bacterial conjunctivitis) and in dermatologic preparations for acne and seborrheic dermatitis (sometimes combined with sulfur). Systemic absorption from topical preparations is small but not zero. Patients with severe past sulfa antibiotic reactions are usually advised against topical sulfa.

Other agents containing the sulfonamide group

Several drugs outside the families covered above contain a sulfonamide group:

Sumatriptan and other triptans โ€” for migraine. They contain a sulfonamide moiety but no arylamine, are not antibacterial, and the cross-reactivity question is the same as for diuretics: low. The prescribing information often carries a historical caution; modern practice in many settings is to use them in patients with non-severe sulfa antibiotic allergy.

Probenecid โ€” historically used to extend the half-life of penicillin and to lower urate in gout. Sulfonamide-containing; cross-reactivity with sulfa antibiotics is generally considered low.

Zonisamide โ€” an antiepileptic drug. Contains a sulfonamide group. Cross-reactivity has been described; caution in patients with severe past sulfa antibiotic reactions is reasonable.

Tamsulosin โ€” a selective ฮฑ1A-adrenergic blocker used for benign prostatic hyperplasia. The structure is a sulfonamide; cross-reactivity has been raised in product labelling but is not a major clinical issue in published data.

Topiramate โ€” an antiepileptic and migraine drug. Technically a sulfamate, not a sulfonamide, but often discussed alongside. It has been associated with a unique syndrome of acute angle-closure glaucoma in rare cases.

The pattern repeats. For most drugs that share the sulfonamide group with sulfa antibiotics but lack the N4 arylamine, cross-reactivity rates in published data are low. The exceptions โ€” sulfasalazine, dapsone (a sulfone, technically), and some patients with severe past reactions โ€” are managed individually. The prescriber decides.

See also